全文1172字,阅读约需4分钟,帮我划重点划重点01诺和诺德的胰高糖素样肽-1受体激动剂司美格鲁肽正式在中国上市,用于长期体重管理。02诺和盈在公立医院的首张处方将于下周在上海开出,定价将参考省挂网价格。03除此之外,诺和盈已进入私立医院渠道,收费为一支1400元左右(一个月用量)。04专家表示,GLP-1类药物有望成为未来肥胖症治疗的主要手段,但患者应前往正规医疗机构进行评估和诊断。05目前,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.